NCT05104788 (NeoIpower) is a Phase 2 clinical trial of Icotinib in Non-Small Cell Lung Cancer, sponsored by Peking University Cancer Hospital & Institute.

Who is sponsoring NCT05104788?

NCT05104788 is sponsored by Peking University Cancer Hospital & Institute.

What drugs are being tested in NCT05104788?

Interventions in NCT05104788: Icotinib, Cisplatin, Carboplatin, Pemetrexed.

What condition does NCT05104788 study?

NCT05104788 studies Non-Small Cell Lung Cancer.

Is NCT05104788 still recruiting?

NCT05104788 is currently recruiting now. Last updated 3 November 2021.

Last reviewed 2021-11-03 · How we verify

NCT05104788: NeoIpower

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Recruiting now Phase 2 Last updated 3 November 2021

What this trial tests

Phase 2 trial testing Icotinib in Non-Small Cell Lung Cancer in 27 participants. Currently enrolling.

Timeline

25 October 2021

Primary endpoint
1 March 2024

1 December 2026

Quick facts

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	25 October 2021
Primary completion	1 March 2024
Estimated completion	1 December 2026
Sites	1 location across China

Drugs / interventions tested

Icotinib — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Pemetrexed — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Peking University Cancer Hospital & Institute

Who can join

Adults 18 to 75, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase II, single-Arm, prospective study of neoadjuvant Icotinib with chemotherapy for the treatment of patients with epidermal growth factor receptor mutation positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.
Lee JM, McNamee CJ, Toloza E, Negrao MV, et al · · 2023 · cited 59× · PMID 37451404 · DOI 10.1016/j.jtho.2023.07.006
Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges.
Kalvapudi S, Vedire Y, Yendamuri S, Barbi J. · · 2023 · cited 19× · PMID 38144524 · DOI 10.3389/fonc.2023.1286104
<i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
Cansouline X, Lipan B, Sizaret D, Tallet A, et al · · 2022 · cited 9× · PMID 35565386 · DOI 10.3390/cancers14092257
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.
Fuorivia V, Attili I, Corvaja C, Asnaghi R, et al · · 2024 · cited 7× · PMID 39330007 · DOI 10.3390/curroncol31090379
Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations.
Liu W, Ren S, Xiao Y, Yang L, et al · · 2022 · cited 7× · PMID 36467102 · DOI 10.3389/fphar.2022.1036334
Perioperative Strategies in Resectable Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations and ALK Rearrangement.
Petrella F, Cara A, Cassina EM, Degiovanni S, et al · · 2025 · cited 2× · PMID 40507325 · DOI 10.3390/cancers17111844
Neoadjuvant, Adjuvant and Perioperative Treatment in Early-Stage Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations: Current Landscape and Future Perspectives.
Koutoukoglou P, Mountzios G. · · 2026 · PMID 41681965 · DOI 10.3390/cancers18030493
Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER).
Lu F, Lv C, Yang X, Zhuo M, et al · · 2025 · PMID 40706271 · DOI 10.1016/j.lungcan.2025.108676

Verify or expand the search:

Other trials of Icotinib

Trials testing the same drug.

NCT06517953 — Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations · Phase 2 · recruiting
NCT05514314 — A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Dise · Phase 2 · unknown
NCT05263947 — Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation · Phase 2 · completed
NCT05132985 — Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma · Phase 2 · not yet recruiting
NCT05007938 — Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer · Phase 2 · active not recruiting

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Peking University Cancer Hospital & Institute trials

Trials by the same sponsor.

NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05104788 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
Last refreshed: 3 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05104788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing